Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 8, 2004. The report serves as a disclosure of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs). It does not contain financial performance data for a fiscal period.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and share ownership disclosures.
Material Changes and Transactions
The filing details several specific transactions regarding directors' interests and employee trust distributions:
- Employee Trust Distributions: The GlaxoSmithKline Employee Trust (GSK Trust) transferred shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 and the Mid Term Incentive Plan.
- 14,306 shares transferred on January 6, 2004.
- 2,031 shares transferred on January 7, 2004.
- 11,736 shares transferred on January 7, 2004 (advised January 8).
- Directors' Share Purchases:
- Mr. J D Coombe, Mrs. G A Coombe, and Sir Peter Job purchased Ordinary Shares via a Single Company ISA on January 6, 2004, at £12.61 per share.
- Mr. J D Coombe acquired 3 additional shares via the ShareReward Plan Dividend Reinvestment element at £12.60 per share.
- Dividend Reinvestment (ADRs):
- Dr. J P Garnier and Dr. T Yamada increased their ADR holdings under the Executive Supplemental Savings Plan following the reinvestment of the dividend paid on January 6, 2004, at $46.72 per share.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It notes that the GSK Trust is a discretionary trust where directors Dr. J-P Garnier and Mr. J D Coombe are interested in shares held in the same capacity as other employees.
Key Facts for Investor Verification
- Verify the total number of shares transferred from the GSK Trust to employee plans during the week of January 6-8, 2004.
- Confirm the share price of £12.61 and £12.60 used for director purchases on January 6, 2004.
- Confirm the ADR price of $46.72 used for dividend reinvestment on January 6, 2004.
- Note that this filing contains no financial performance metrics (revenue, earnings, cash flow) for the period.